Edgen Stock·Mar 31 2026, 17:24Key Takeaways:
(SEATTLE) — Parse Biosciences, a part of QIAGEN, announced the commercial launch of its Evercode Whole Transcriptome FFPE kits on Tuesday, a move that enables researchers to perform whole transcriptome single-cell RNA sequencing on preserved tissue samples. The new technology is designed to unlock vast archives of formalin-fixed, paraffin-embedded (FFPE) tissues for complex cellular analysis.
"This breakthrough allows the scientific community to retrospectively analyze samples with a resolution that was previously impossible," said Alex Feldman, CEO of Parse Biosciences, in a statement. "It bridges the gap between archived FFPE tissues and the most advanced single-cell sequencing techniques."
The Evercode technology utilizes a proprietary barcoding system to enable whole transcriptome analysis from FFPE samples, which are notoriously difficult to work with due to RNA degradation and chemical modifications from the preservation process. This development could significantly expand the scope of translational research in fields like oncology and neuroscience, where FFPE samples are a standard for long-term storage.
The launch positions QIAGEN to compete with other major players in the genomics space, such as 10x Genomics and NanoString Technologies, who are also developing solutions for FFPE sample analysis. The ability to analyze the whole transcriptome, rather than targeted gene panels, provides a more comprehensive view of cellular states and is a key differentiator. For investors, this could enhance QIAGEN's competitive position and open up a multi-billion dollar market of archived tissues.
This article is for informational purposes only and does not constitute investment advice.
